Ibald-Mulli A, Seufert J, Grimsmann JM, Laimer M, Bramlage P, Civet A, Blanchon M, Gosset S, Templier A, Paar WD, Zhou FL, Lanzinger S. Identification of Predictive Factors of Diabetic Ketoacidosis in Type 1 Diabetes Using a Subgroup Discovery Algorithm. Diabetes Obes Metab. 2023 Mar 3. doi: 10.1111/dom.15039.

Eckert AJ, Bramlage P, Danne T, Näke A, Hummel M, Schwab KO, Mühldorfer S, Buchal G, Müller A, Holl RW. The Use of Insulin Preparations-an Evaluation of the DPV Registry. Dtsch Arztebl Int. 2022 Sep 23;119(38):249-250.

Kress S, Bramlage P, Holl RW, Möller CD, Mühldorfer S, Reindel J, Seufert J, Landgraf R, Merker L, Meyhöfer SM, Danne T, Fasching P, Mertens PR, Wanner C, Lanzinger S. Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry. Diabetes Obes Metab. 2023 Mar;25(3):776-784.

Bramlage P, Tittel SR, Müther S, Reinhart-Steininger B, Haberland H, Khodaverdi S, Zimny S,  Ohlenschläger U, Lanzinger S, Haak T. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes. Acta Diabetol. 2022 Nov;59(11):1453-1460.

Grimsmann JM, Tittel SR, Bramlage P, Mayer B, Fritsche A, Seufert J, Laimer M, Zimny S, Meyhoefer SM, Hummel M, Holl RW. Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Follow-up Registry. Diabetes Obes Metab. 2022 Nov;24(11):2253-2262.

Lanzinger S, Best F, Bergmann T, Laimer M, Lipovsky B, Danne T, Zimny S, Bramlage P, Meyhöfer S, Holl RW.

Dynamics of Hemoglobin A1c, Body Mass Index, and Rates of Severe Hypoglycemia in 4434 Adults with Type 1 or Type 2 Diabetes After Initiation of Continuous Glucose Monitoring. Diabetes Technol Ther. 2022 Oct;24(10):763-769.

Seufert J, Lanzinger S, Danne T, Bramlage P, Schmid SM, Kopp F, Kress S, Fasching P, Schäfer C, Holl RW; DPV Initiative. Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis. Diabetes Obes Metab. 2021. 

van Mark G, Tittel SR, Welp R, Gloyer J, Sziegoleit S, Barion R, Jehle PM, Erath D, Bramlage P, Lanzinger S. DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002215. 

Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, Holl RW. Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis. BMC Nephrol. 2021

Biester T, Grimsmann JM, Heidtmann B, Rami-Merhar B, Ermer U, Wolf J, Freff M, Karges B, Agena D, Bramlage P, Danne T, Holl RW. Intermittently Scanned Glucose Values for Continuous Monitoring: Cross-Sectional Analysis of Glycemic Control and Hypoglycemia in 1809 Children and Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 2021

van Mark G, Tittel SR, Sziegoleit S, Putz FJ, Durmaz M, Bortscheller M, Buschmann I, Seufert J, Holl RW, Bramlage P. Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases. Ther Adv Endocrinol Metab 2020.

Bramlage P, Lanzinger S, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Holl RW, Seufert J. Renal function deterioration in adult patients with type-2 diabetes. BMC Nephrology 2020.

Bramlage et al. The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany. BMJ Open Diabetes Res Care 2020. 

Sandig et al. Continous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Date from the German/Austrian Prospective Diabetes Follow-Up Registry. Diabetes Technol Ther 2020.

Hartmann B et al. Treatment intensification strategies after initial Metformin therapy in adult patients with type-2 diabetes – results of the DPV and DIVE registries. Acta Diabetologia 2019.

van Mark G et al. Characteristics of patients with type-1 or type-2 diabetes receiving Insulin Glargine U300: An analysis of 7268 patients based on the DPV and DIVE registries. Advances in Therapy 2020.

Bramlage P et al. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease – an analysis of the German DPV and DIVE databases. Cardiovascular Diabetology 2019.

van Mark G et al. Patient and disease characteristics of adult patients with type 1 diabetes in Germany – an analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism 2019.

Hartmann B et al. Regional differences in type 2 diabetes treatment and outcomes in Germany-An analysis of the German DPV and DIVE registries. Diabetes Metab Res Rev. 2018 Nov;34(8):e3049.

Hartmann B et al. Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries. PLoS One 2017; 12: e0183235.

Bohn B et al. Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300? Eine multizentrische Analyse von 9.232 Glargin U100/300 Patienten aus den Diabetesregistern DPV und DIVE. Wien Med Wochenschr 2017. doi: 10.1007/s10354-017-0589-8.

Bramlage P et al. Determinants of weight control in patients on basal insulin treatment – an analysis of the DIVE registry. BMJ Open Diabetes Research & Care 2017; 5: e000301.

Bramlage P et al. Dyslipidaemia and its treatment in patients with type 2 diabetes – a joint analysis of the German DIVE and DPV registries. Diabetes Obes Metab. 2016 Sep 4. doi: 10.1111/dom.12783.

Bluhmki T et al. Time-to-event methodology improved statistical evaluation in register-based health services research. J Clin Epidemiol 2017; 82: 103-111.

Bramlage P et al. Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy. Diabetes Res Clin Pract. 2016;116:127-35.

Danne T et al. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord. 2015 Oct 7;15:54.

Danne T et al. [„DIabetes Versorgungs-Evaluation“ (DIVE)–a national quality assurance initiative at physicians providing care for patients with diabetes]. Dtsch Med Wochenschr. 2013;138:934-9.